Viromed Medical AG partners with NEBU-TEC to distribute PulmoPlas® cold plasma technology for veterinary respiratory diseases, targeting equine market with innovativeViromed Medical AG partners with NEBU-TEC to distribute PulmoPlas® cold plasma technology for veterinary respiratory diseases, targeting equine market with innovative

Viromed Medical Partners with NEBU-TEC to Distribute PulmoPlas for Veterinary Use

2026/05/19 06:34
2 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Viromed Medical AG, a medical technology company specializing in cold plasma technology, has entered into an exclusive global distribution partnership with NEBU-TEC International med. Produkte Eike Kern GmbH to commercialize its PulmoPlas® platform for veterinary applications. The collaboration will integrate Viromed’s cold plasma technology with NEBU-TEC’s inhalation and nebulization devices, focusing initially on pulmonary diseases in horses.

The partnership grants NEBU-TEC worldwide exclusive distribution rights for veterinary use of PulmoPlas®, which combines cold plasma with aerosol delivery. According to the announcement, the market launch for PulmoPlas® vet is expected later in 2026, with no regulatory approval required for veterinary applications. The companies believe this addresses a significant market need, particularly in the European equine market and equestrian sports, where respiratory conditions are common among horses.

Viromed’s CEO Uwe Perbandt stated that the partnership represents an important step in international commercialization, opening up new fields in veterinary medicine and potentially human medicine later. NEBU-TEC’s Managing Director Eike Kern highlighted that combining inhalation with cold plasma creates innovative therapeutic possibilities for both animals and humans.

The devices used by NEBU-TEC are Class IIa medical devices under the EU Medical Device Regulation (MDR), which would allow future human use of PulmoPlas® med with the same nebulization technology. Viromed, which has been publicly traded since October 2022, is expanding its strategic partnerships in cold plasma technology through this agreement.

For more information, visit Viromed Medical AG or NEBU-TEC. The original press release is available on NewMediaWire.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Viromed Medical Partners with NEBU-TEC to Distribute PulmoPlas for Veterinary Use.

The post Viromed Medical Partners with NEBU-TEC to Distribute PulmoPlas for Veterinary Use appeared first on citybuzz.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

No Chart Skills? Still Profit

No Chart Skills? Still ProfitNo Chart Skills? Still Profit

Copy top traders in 3s with auto trading!